In this study 43 patients with idiopathic nephrotic syndrome were randomly distributed into 2 age- and sex-matched groups. The first group was given fluvastatin while the second was used as control. The cases in the 2 groups were evaluated clinically, biochemically (creatinine clearance, albumin, 24-hour proteinuria, and lipogram), neurologically, and histopathologically (examination of renal biopsies obtained basally and after 1 year of treatment with fluvastatin). In the fluvastatin-treated group but not in the control group, we observed a significant reduction in cholesterol, low-density lipoprotein, and triglyceride. Clinical and laboratory assessment showed satisfactory tolerance of the drug by the patients. Proteinuria, serum albumin and creatinine clearance values were significantly better in the statin-treated patients. There was no difference in glomerular sclerosis between the 2 groups while interstitial fibrosis and renal fat deposits were less in the statin-treated group. The reduction in renal fat deposits in the statin-treated group was highly significant, while that of interstitial fibrosis was not. We conclude that: (1) statin can be safely and effectively used in the treatment of dyslipidemia in patients with persistent idiopathic nephrotic syndrome; (2) control of dyslipidemia in nephrotic patients is associated with better control of proteinuria and creatinine clearance; (3) statin treatment may cause regression of renal fat deposits in patients with nephrotic syndrome, and (4) longer term studies are still required to study further possible beneficial effects on renal histology and disease progression.

Keywords:
Nephrotic syndrome, Dyslipidemia, Statin, Renal scarring
1.
Joven J, Vilella E: Hyperlipidemia of the nephrotic syndrome – The search for a nephrotic factor. Nephrol Dial Transplant 1995;10:314–316.
2.
O’Donnell MP, Kasiske BL, Kim Y, Atluru D, Kenne WF: Lovastatin inhibits proliferation of rat mesangial cells. J Clin Invest 1993;91:83–87.
3.
Sharma P, Reddy K, Franki N, Sanwal V, Sankaran R, Ahuja TS, Gibbons N, Mattana J, Singhal PC: Native and oxidized low density lipoproteins modulate mesangial cell apoptosis. Kidney Int 1996;50:1604–1611.
4.
Nishida Y, Oda H, Yorioka N: Effect of lipoproteins on mesangial cell proliferation. Kidney Int 1999;56(suppl 71):S51–S53.
5.
Massy ZA, Ma JZ, Loius TA, Kasiske BL: Lipid-lowering therapy in patients with renal disease. Kidney Int 1995;48:188–198.
6.
Keane WF, St Peter JV, Kasiske BL: Is the aggressive management of hyperlipidemia in nephrotic syndrome mandatory? Kidney Int Suppl 1992;38:134–141.
7.
Lillie RD, Ashburn LL: Supersaturated solutions of fat stains in dilute isopropanol for demonstration of acute fatty degeneration not shown by Herxheimer’s technic. Arch Pathol 1943;36:432.
8.
Wheeler DC: Lipids – What is the evidence for their role in progressive renal disease. Nephrol Dial Transplant 1995;10:14–16.
9.
Warwick GL, Caslake MJ, Boulton-Jones JM, Dagen M: Low-density lipoprotein metabolism in the nephrotic syndrome. Metabolism 1990;39:187–192.
10.
Matzkies FK, Bahner U, Teschner M, Hohage H, Heidland A, Schaefer RM: Efficiency of 1-year treatment with fluvastatin in hyperlipidemic patients with nephrotic syndrome. Am J Nephrol 1999;19:492–494.
11.
Olbricht CJ, Koch KM: Treatment of hyperlipidemia in nephrotic syndrome: Time for a change? Nephron 1992;62:125–129.
12.
Todd PA, Goa KL: Kinetics of statins. Drugs1991;42:65–89.
13.
Jokubaitis LA: Fluvastatin in combination with other lipid-lowering agents. Br J Clin Pract Suppl 1996;77A:28–32.
14.
Wanner C, Bohler J, Eckardt HG, Weiland H, Schollmeyer P: Effects of simvastatin on lipoprotein(a) and lipoprotein composition in patients with nephrotic syndrome. Clin Nephrol 1994;41:138–143.
15.
Hattori M, Ito K, Kawaguchi H: Treatment with a combination of low-density lipoprotein apheresis and pravastatin of a patient with drug resistant nephrotic syndrome due to focal segmental glomerulosclerosis. Pediatr Nephrol 1993;7:196–198.
16.
Lam KS, Cheng IK, Janus ED, Pang RW: Cholesterol-lowering therapy may retard the progression of diabetic nephropathy. Diabetologia 1995;38:604–609.
17.
Chan PC, Robinson JD, Yeung WC: Lovastatin in glomerulonephritis patients with hyperlipidemia and heavy proteinuria. Nephrol Dial Transplant 1992;7:93–99.
18.
Jacobson TA, Chin MM, Fromell GJ, Jokubaitis LA, Amorosa LF: Fluvastatin with and without niacin for hypercholesterolemia. Am J Cardiol 1994;74:149–154.
19.
Wheeler DC, Bernard DB: Lipid abnormalities in the nephrotic syndrome: Causes, consequences, and treatment. Am J Kidney Dis 1994;23:331–346.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.